Literature DB >> 2813417

Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid.

M L Bryant1, R O Heuckeroth, J T Kimata, L Ratner, J I Gordon.   

Abstract

Myristoyl-CoA:protein N-myristoyltransferase (NMT; EC 2.3.1.97) catalyzes the cotranslational linkage of myristate to the N-terminal glycine residues of several cellular, viral, and oncoproteins. We have recently synthesized a series of sulfur- and oxygen-substituted analogs of myristic acid that are similar in length to the 14:0 fatty acid yet have hydrophobicities equivalent to dodecanoate or decanoate. Previous in vitro enzyme assays and metabolic labeling studies indicate that some of these analogs are excellent substrates for NMT and are incorporated into subsets of cellular N-myristoyl proteins. Their sequence-specific incorporation probably arises from cooperative interactions between the acyl CoA and peptide binding sites of NMT. The human immunodeficiency virus 1 (HIV-1) and Moloney murine leukemia virus (MoMLV) depend on myristoylation of gag polyprotein precursors for assembly. We have tested four analogs--12-methoxydodecanoic acid, 10-propoxydecanoic acid, 5-octyloxypentanoic acid, and 11-ethylthioundecanoic acid--for their ability to block replication of these retroviruses. All reduce HIV-1 replication when incubated with CD4+ H9 cells for 10 days at 10-100 microM. 12-Methoxydodecanoic acid is most effective, producing a concentration-dependent decrease in (i) reverse transcriptase activity (to levels that were 5-10% of control at 20-40 microM), (ii) p24 levels, and (iii) syncytia formation. This degree of inhibition of HIV-1 replication is equivalent to that seen with 5 microM 3'-azido-3'-deoxythymidine and is accomplished without apparent toxicity, as measured by cell viability, protein, and nucleic acid synthesis. 5-Octyloxypentanoic acid inhibits MoMLV assembly in a dose-dependent fashion without accompanying cellular toxicity, while 12-methoxydodecanoic acid has no effect. These data suggest that the use of cellular NMT activity to deliver analogs of myristate with altered physical-chemical properties to proteins that undergo this cotranslational modification may represent an effective anti-viral therapeutic strategy as well as a way to investigate the role of covalently bound fatty acid in viral assembly.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2813417      PMCID: PMC298346          DOI: 10.1073/pnas.86.22.8655

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Myristylation of picornavirus capsid protein VP4 and its structural significance.

Authors:  M Chow; J F Newman; D Filman; J M Hogle; D J Rowlands; F Brown
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

2.  Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.

Authors:  H G Göttlinger; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

3.  Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus.

Authors:  A Rein; M R McClure; N R Rice; R B Luftig; A M Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

4.  Substrate specificity of eukaryotic signal peptidase. Site-saturation mutagenesis at position -1 regulates cleavage between multiple sites in human pre (delta pro) apolipoprotein A-II.

Authors:  R J Folz; S F Nothwehr; J I Gordon
Journal:  J Biol Chem       Date:  1988-02-05       Impact factor: 5.157

5.  Acylation of proteins with myristic acid occurs cotranslationally.

Authors:  C Wilcox; J S Hu; E N Olson
Journal:  Science       Date:  1987-11-27       Impact factor: 47.728

6.  Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids.

Authors:  S S Rhee; E Hunter
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

7.  HIV F/3' orf encodes a phosphorylated GTP-binding protein resembling an oncogene product.

Authors:  B Guy; M P Kieny; Y Riviere; C Le Peuch; K Dott; M Girard; L Montagnier; J P Lecocq
Journal:  Nature       Date:  1987 Nov 19-25       Impact factor: 49.962

8.  Purification and characterization of yeast myristoyl CoA:protein N-myristoyltransferase.

Authors:  D A Towler; S P Adams; S R Eubanks; D S Towery; E Jackson-Machelski; L Glaser; J I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

9.  Myristoyl CoA:protein N-myristoyltransferase activities from rat liver and yeast possess overlapping yet distinct peptide substrate specificities.

Authors:  D A Towler; S P Adams; S R Eubanks; D S Towery; E Jackson-Machelski; L Glaser; J I Gordon
Journal:  J Biol Chem       Date:  1988-02-05       Impact factor: 5.157

10.  Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos.

Authors:  J R Sanes; J L Rubenstein; J F Nicolas
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

View more
  23 in total

1.  Functional analysis of protein N-myristoylation: metabolic labeling studies using three oxygen-substituted analogs of myristic acid and cultured mammalian cells provide evidence for protein-sequence-specific incorporation and analog-specific redistribution.

Authors:  D R Johnson; A D Cox; P A Solski; B Devadas; S P Adams; R M Leimgruber; R O Heuckeroth; J E Buss; J I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Myristoylation of the RING finger Z protein is essential for arenavirus budding.

Authors:  Mar Perez; Dori L Greenwald; Juan Carlos de la Torre
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

3.  Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences.

Authors:  L E Henderson; M A Bowers; R C Sowder; S A Serabyn; D G Johnson; J W Bess; L O Arthur; D K Bryant; C Fenselau
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  N myristoylation of the spleen necrosis virus matrix protein is required for correct association of the Gag polyprotein with intracellular membranes and for particle formation.

Authors:  T A Weaver; A T Panganiban
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

5.  Protein N-myristoylation in Escherichia coli: reconstitution of a eukaryotic protein modification in bacteria.

Authors:  R J Duronio; E Jackson-Machelski; R O Heuckeroth; P O Olins; C S Devine; W Yonemoto; L W Slice; S S Taylor; J I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

6.  Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.

Authors:  M Bryant; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

Review 7.  Molecular determinants that regulate plasma membrane association of HIV-1 Gag.

Authors:  Vineela Chukkapalli; Akira Ono
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

8.  Coenzyme A dependent myristoylation and demyristoylation in the regulation of bovine spleen N-myristoyltransferase.

Authors:  R V Raju; R K Sharma
Journal:  Mol Cell Biochem       Date:  1996-05-24       Impact factor: 3.396

9.  Recombinant bovine spleen myristoyl CoA: protein N-myristoyltransferase.

Authors:  R V Raju; R S Datla; R Kakkar; R K Sharma
Journal:  Mol Cell Biochem       Date:  1998-12       Impact factor: 3.396

10.  Use of photoactivatable peptide substrates of Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase (Nmt1p) to characterize a myristoyl-CoA-Nmt1p-peptide ternary complex and to provide evidence for an ordered reaction mechanism.

Authors:  D A Rudnick; W J Rocque; C A McWherter; M V Toth; E Jackson-Machelski; J I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.